Latest Lead News

Perpetual Resources has launched a prospectus to enable trading of new options issued alongside a recent $1.6 million placement, aiming to unlock liquidity while outlining key risks for investors.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Finexia Financial Group has restated its FY24 financials due to a material error in expense accruals and reduced the value of its Stayco investment by $4 million following an external valuation review.

Burgundy Diamond Mines posted a $29.5 million net loss for H1 2025, driven by operational disruptions and weaker diamond prices, leading to a temporary halt of mining at Point Lake. The company is navigating liquidity challenges with new financing arrangements while restructuring its operations.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Aeris Environmental Ltd reported a modest revenue increase for FY2025 but saw its operating loss widen sharply to $4.12 billion, raising concerns about its financial stability.

Dataworks Group Limited reported a modest revenue increase and a reduced net loss for FY25, underpinned by major contract wins in Canada and Australia. The company is targeting cashflow positivity in the first half of FY26 following operational efficiencies and capital raises.

Elanor Investors Group reported a substantial $157.8 million net loss for FY24 amid asset devaluations and debt covenant breaches, prompting a strategic recapitalisation and leadership transition.

OMG Group Limited reported a robust 63.3% revenue increase to $4.13 million in FY2025, driven by strategic acquisitions and expanded retail partnerships. The company also narrowed its losses by 29%, setting the stage for sustained growth in FY2026.

Spectur Limited reported a 6% revenue increase to $8.7 million and slashed its net loss by 70% to $779,000 in FY25, driven by operational restructuring and a shift toward recurring revenue streams.

Coventry Group Ltd reported a challenging FY25 with a 1.7% revenue decline and a 40.9% drop in underlying EBITDA, culminating in a $29.6 million net loss. The company is now targeting over $20 million EBITDA in FY26 through aggressive cost reductions and operational recalibration.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.